Amphotericin B-loaded Eudragit RL100 nanoparticles coated with hyaluronic acid for the treatment of vulvovaginal candidiasis

Carolina Mirtes Melo,Jéssica Ferreira Cardoso,Fernanda Barçante Perassoli,Ari Soares de Oliveira Neto,Luccas Moreira Pinto,Maria Betânia de Freitas Marques,Wagner da Nova Mussel,Juliana Teixeira Magalhães,Sandra Aparecida de Lima Moura,Marcelo Gonzaga de Freitas Araújo,Gisele Rodrigues Da Silva
DOI: https://doi.org/10.1016/j.carbpol.2019.115608
2020-02-15
Abstract:The treatment of vulvovaginal candidiasis (VVC) is based on oral and vaginal formulations which show limited effectiveness. In this study, amphotericin B-loaded Eudragit RL100 nanoparticles coated with hyaluronic acid (AMP EUD nanoparticles/HA) were developed to overcome the drawbacks of the conventional formulations. AMP EUD nanoparticles/HA were synthesized by nanoprecipitation, formulated by statistical experimental design, and characterized. AMP release from EUD nanoparticles/HA and its antifungal activity in a murine model of VVC were evaluated. Nanoparticles showed 147.6 ± 16.7 nm of diameter, 0.301 ± 0.09 of polydispersity index, - 29.9 ± 3.76 mV of zeta potential, and 87.27 % of encapsulation efficiency. They released about 81 % of AMP in 96 h; and provided the elimination of 100 % of the vaginal fungal burden in 24 h. It was suggested that the AMP EUD nanoparticles/HA penetrated into the vaginal epithelium via CD44 receptors. These AMP EUD nanoparticles/HA represent a non-conventional vaginal formulation to improve the treatment of VVC.
What problem does this paper attempt to address?